Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...
April 26 (Reuters) - AbbVie (ABBV.N), opens new tab expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as ...
Shares of AbbVie (NYSE:ABBV) were down 6% in afternoon trading Friday in the wake of the drugmaker's Q1 earnings report and news that Cigna (CI) plans to offer a biosimilar of AbbVie’s top-selling ...
AbbVie posted first-quarter results largely as projected, and we don’t expect any major changes to our fair value estimate. With the arrival of the first U.S. biosimilar to Humira, AbbVie’s results ...
AbbVie is a leading pharmaceutical company with a diverse portfolio of products and strong revenue growth. The company has a solid track record of increasing dividends and offers an attractive current ...
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday, when AbbVie ...
(Reuters) - CVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will ...
NEW YORK, Jan 27 (Reuters) - Abbott Laboratories reported stronger-than-expected fourth-quarter results, helped by lower taxes and reduced expenses, but weak U.S. sales of its Humira arthritis drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback